Bench-To-Clinic Development of Imageable Drug-Eluting Embolization Beads: Finding the Balance
Year: 2018
Type: article
Abstract: This review describes the historical development of an imageable spherical embolic agent and focuses on work performed in collaboration between Biocompatibles UK Ltd (a BTG International group company) and the NIH to demonstrate radiopaque bead utility and bring a commercial offering to market that meets a clinical need. Various chemistries have been investigated and multiple prototypes evaluated in search of an optimized product with the right balance of handling and imaging properties. Herein, we describe the steps taken in the development of DC Bead LUMI™, the first commercially available radiopaque drug-eluting bead, ultimately leading to the first human experience of this novel embolic agent in the treatment of liver tumors.
Source: Future Oncology
Institutions: BTG International (United Kingdom), National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering, National Cancer Institute, Center for Cancer Research, National Institutes of Health Clinical Center, Children's National, Sheikh Zayed Institute for Pediatric Surgical Innovation
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2811336368